GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
GoodRx Holdings Inc. (GDRX) PT Lowered to $30 at Goldman Sachs
March 1, 2022 6:58 AM ESTGoldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $30.00 (from $43.00) while maintaining a Buy rating following results.
The analyst commented, "We reiterate our Buy rating but lower our PT from $43 to $30 to reflect both lowered operating... More
GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan
March 1, 2022 4:58 AM ESTJPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.
The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More
GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook
February 28, 2022 5:31 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.
Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More
